• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

    2/6/25 8:30:00 PM ET
    $COR
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $COR alert in real time by email

    Transaction Highlights

    • Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares
    • Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares
    • Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional cash proceeds at maturity. These remaining prepaid variable share forward contracts are mainly scheduled to mature during March, June and September of calendar year 2025.
    • Use of proceeds will primarily be for debt paydown, as the Company proactively seeks to address its debt maturities in fiscal year 2026, and for general corporate purposes

    Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into with various financial institutions, with respect to shares of Cencora, Inc. (NYSE:COR). Under these transactions, the Company had previously received cash payments in an aggregate amount of approximately $1.1 billion on or about the dates of first entering into them. The transactions were scheduled to mature during March and June of calendar year 2026.

    As part of the early settlement of the transactions prior to their scheduled maturities, WBA will deliver to the financial institutions an aggregate of approximately 6.1 million shares of Cencora, while paying a net aggregate cash payment of approximately $20 million. The transaction fulfills the Company's obligations to deliver shares at a future date to each financial institution participating in the early settlement. These contracts have accreted cash value to the Company as a result of participation in the appreciation of Cencora's stock since entering the transactions in 2023. The early settlement together with the concurrent share sale realizes the embedded cash value that exists in the prepaid variable share forwards.

    Concurrent with these early settlements, WBA today announced that it has sold shares of Cencora common stock in an unregistered block trade pursuant to Rule 144 for proceeds of approximately $265 million, and has sold additional shares in a share repurchase by Cencora for additional proceeds of approximately $50 million.

    Proceeds to WBA will be used primarily for debt paydown and general corporate purposes. The proceeds from these transactions as well as other actions, including the recent suspension of the dividend, further help position the Company to address its upcoming debt maturities in fiscal 2026.

    Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 10 percent to approximately six percent.

    The sale has no impact to the long-term partnership between the two companies. Walgreens Boots Alliance remains fully committed to the strategic, mutually beneficial relationship with Cencora, which has been a strong and trusted partner since 2013. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on Cencora's Board of Directors.

    About Walgreens Boots Alliance

    Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.

    A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.

    WBA employs approximately 311,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.

    More Company information is available at www.walgreensbootsalliance.com.

    (WBA-GEN)

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250206482504/en/

    WBA Media Relations

    USA / Jim Cohn, Jim.cohn@wba.com

    WBA Investor Relations

    Eric Wasserstrom, Investor.relations@wba.com

    Get the next $COR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COR
    $WBA

    CompanyDatePrice TargetRatingAnalyst
    Cencora Inc.
    $COR
    4/28/2026Mkt Perform
    William Blair
    Cencora Inc.
    $COR
    1/29/2026$400.00Equal-Weight → Overweight
    Morgan Stanley
    Cencora Inc.
    $COR
    1/22/2026$440.00Hold → Buy
    Jefferies
    Cencora Inc.
    $COR
    12/9/2025$400.00Overweight
    Barclays
    Cencora Inc.
    $COR
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    Walgreens Boots Alliance Inc.
    $WBA
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    Cencora Inc.
    $COR
    12/4/2024$280.00Outperform
    Mizuho
    Cencora Inc.
    $COR
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $COR
    $WBA
    SEC Filings

    View All

    SEC Form 11-K filed by Cencora Inc.

    11-K - Cencora, Inc. (0001140859) (Filer)

    6/18/26 2:03:55 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    6/15/26 5:00:27 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Inc. filed SEC Form 8-K: Leadership Update, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cencora, Inc. (0001140859) (Filer)

    5/29/26 5:10:04 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Tyler Lauren M bought $148,626 worth of shares (550 units at $270.23), increasing direct ownership by 14% to 4,359 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    6/24/26 4:04:15 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Director Durcan Dermot Mark bought $1,096,760 worth of shares (4,000 units at $274.19), increasing direct ownership by 14% to 31,767 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    6/22/26 4:05:32 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Director Durcan Dermot Mark bought $1,065,040 worth of shares (4,000 units at $266.26), increasing direct ownership by 17% to 27,767 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    5/28/26 4:23:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Cencora

    William Blair initiated coverage of Cencora with a rating of Mkt Perform

    4/28/26 7:43:49 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Cencora from Equal-Weight to Overweight and set a new price target of $400.00

    1/29/26 6:57:57 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora upgraded by Jefferies with a new price target

    Jefferies upgraded Cencora from Hold to Buy and set a new price target of $440.00

    1/22/26 8:20:03 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $COR
    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Battaglia Silvana was granted 58 shares, increasing direct ownership by 0.25% to 23,624 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    7/7/26 4:01:30 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Executive Vice President Campbell Elizabeth S was granted 50 shares, increasing direct ownership by 0.16% to 30,756 units (SEC Form 4)

    4 - Cencora, Inc. (0001140859) (Issuer)

    7/7/26 4:00:33 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Financial Officer Boratto Eva C

    4 - Cencora, Inc. (0001140859) (Issuer)

    6/30/26 4:20:09 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the ca

    7/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Samantha Hammock as Chief Human Resources Officer

    Silvana Battaglia to retire after distinguished 7-year tenure Cencora, Inc. (NYSE:COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026. "During her seven years of leadership, Silvana has made critical, lasting contributions to Cencora during a time of significant growth," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "Her global vision strengthened our culture and championed meaning

    6/15/26 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer

    Cencora reaffirms fiscal 2026 and long-term financial guidance Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced public company executive with considerable financial and operational experience across the healthcare and consumer sectors. She most recently served as Chief Financial Offic

    5/27/26 6:55:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cencora Inc.

    SC 13G/A - Cencora, Inc. (0001140859) (Subject)

    11/14/24 1:22:34 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $COR
    $WBA
    Financials

    Live finance-specific insights

    View All

    Cencora Announces Date and Time for Third Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer Eva C. Boratto, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company’s website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the ca

    7/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Reports Fiscal 2026 Second Quarter Results

    Revenue of $78.4 billion for the Second Quarter, a 3.8 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $8.40 and Adjusted Diluted EPS of $4.75 Adjusted Diluted EPS Guidance Range Raised to $17.65 to $17.90 for Fiscal 2026 Cencora Expects to Repurchase $1 Billion in Shares by the End of Calendar 2026 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2026 second quarter ended March 31, 2026, revenue increased 3.8 percent year-over-year to $78.4 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $8.40 for the second quarter of fiscal 2026 compared to $3.68 in the prior year second quarter. Adjus

    5/6/26 6:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release

    Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call v

    4/1/26 4:30:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    $COR
    $WBA
    Leadership Updates

    Live Leadership Updates

    View All

    Cencora Announces Samantha Hammock as Chief Human Resources Officer

    Silvana Battaglia to retire after distinguished 7-year tenure Cencora, Inc. (NYSE:COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026. "During her seven years of leadership, Silvana has made critical, lasting contributions to Cencora during a time of significant growth," said Robert P. Mauch, President and Chief Executive Officer of Cencora. "Her global vision strengthened our culture and championed meaning

    6/15/26 4:15:00 PM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Appoints Eva Boratto as Executive Vice President and Chief Financial Officer

    Cencora reaffirms fiscal 2026 and long-term financial guidance Cencora, Inc. (NYSE:COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Ms. Boratto is an experienced public company executive with considerable financial and operational experience across the healthcare and consumer sectors. She most recently served as Chief Financial Offic

    5/27/26 6:55:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care

    Cencora Announces Financial Leadership Transition

    Cencora reaffirms fiscal 2026 financial guidance Cencora, Inc. (NYSE:COR) today announced that James F. Cleary will retire as Executive Vice President and Chief Financial Officer effective June 30, 2026. Cencora has engaged an executive search firm to identify and evaluate potential successors from internal and external candidates. Mr. Cleary will assist in the search process and will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition. Mr. Cleary, 62, has served as Cencora's CFO since November 2018. He joined the Company in February 2015, following its acquisition of MWI Veterinary Supply, where he had served as Chief Executive Officer for over a de

    3/17/26 8:30:00 AM ET
    $COR
    Other Pharmaceuticals
    Health Care